Summary of Research: Dupilumab Safety for Treating Infants to Adults with Moderate-to-Severe Atopic Dermatitis

This is a summary of the original article "The safety data of dupilumab for the treatment of moderate-to-severe atopic dermatitis in infants, children, adolescents, and adults". Atopic dermatitis (AD) is an inflammatory disease affecting the skin of people of all ages. Dupilumab is a drug used to treat infants, children, adolescents, and adults who have moderate-to-severe AD. Since patients with AD often require continuous, long-term treatment, it is important to understand the short- and long-term treatment risks. This summary provides a plain-language overview of the original article, which evaluated the side effects reported by patients who received dupilumab or placebo (inactive treatment) for up to 5 years in 8 clinical trials. Side effect rates were similar between dupilumab and placebo in short-term studies in all age groups. There was no increase in the number of reported side effects with long-term versus short-term treatment. Injection-site reactions, colds, and conjunctivitis side effects were more common in dupilumab versus placebo. One adult patient treated with dupilumab developed a delayed allergic reaction. Blood and urine tests indicated no need for laboratory testing during treatment. The study confirms that the overall safety of dupilumab over 8 clinical trials was consistent with previously presented safety data.